PubMed · 2021 · 18 citations · 0 references
Open access
PharmacyInfectious DiseasesPharmacotherapyInfectious Disease PharmacotherapyMolecular VirologyVirologyAntiviral AgentsAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyInterferon-based TherapyTreatmentAntiviral Safety AssessmentEligible PersonsSars-cov-2 Antiviral TherapySars-cov-2 InfectionTreatment Of Coronavirus Infections
5.0 (IQR 4.5; 5.5) days in the SOC group (HR 2.11; 95% CI 1.04-4.31; P=0.038). The rate of viral elimination on Day 5 in the favipiravir group was significantly higher than in SOC group: 81.2% vs. 67.9% (RR 1.22; 05% CI 1.00-1.48; P=0.022). The rate of clinical improvement on Day 7 in the favipiravir group was 1.5-fold higher than in SOC group: 52.7% vs. 35.8% (RR 1.50; 95% CI 1.02-2.22; P=0.020). Favipiravir was well-tolerated and the most common adverse reactions were asymptomatic hyperuricemia, transient elevation of ALT & AST, and mild gastrointestinal disorders. Favipiravir was superior to the SOC in shortening the time to clinical improvement in patients with mild to moderate COVID-19.